{
    "organizations": [],
    "uuid": "e6ea976f9cc95a4d42bd9cc24d49ae3b5cfb6e1e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sage-therapeutics-qtrly-net-loss-p/brief-sage-therapeutics-qtrly-net-loss-per-share-1-75-idUSASB0C6X3",
    "ord_in_thread": 0,
    "title": "BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 22, 2018 / 12:01 PM / Updated 8 minutes ago BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75 Reuters Staff Feb 22 (Reuters) - Sage Therapeutics Inc: * SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE * ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING * ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING * QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $1.75 * CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES AS OF DEC 31, 2017 WERE $518.8 MILLION, VERSUS $397.5 MILLION AT DECEMBER 31, 2016 * EXPECTS OPERATING EXPENSES TO INCREASE YEAR OVER YEAR IN 2018 * Q4 EARNINGS PER SHARE VIEW $-1.99 -- THOMSON REUTERS I/B/E/S * SAGE -EXPECTS EXISTING CASH,CASH EQUIVALENTS, MARKETABLE SECURITIES, OTHER SALES TO ENABLE CO TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO 2020 Source text for Eikon: Further company coverage:",
    "published": "2018-02-22T13:58:00.000+02:00",
    "crawled": "2018-02-22T14:15:42.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "qtrly",
        "net",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "sage",
        "therapeutic",
        "inc",
        "sage",
        "therapeutic",
        "announces",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "provides",
        "pipeline",
        "update",
        "track",
        "submit",
        "new",
        "drug",
        "application",
        "brexanolone",
        "postpartum",
        "depression",
        "1h",
        "following",
        "meeting",
        "track",
        "submit",
        "new",
        "drug",
        "application",
        "brexanolone",
        "postpartum",
        "depression",
        "1h",
        "following",
        "meeting",
        "qtrly",
        "net",
        "loss",
        "per",
        "share",
        "basic",
        "diluted",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "dec",
        "million",
        "versus",
        "million",
        "december",
        "expects",
        "operating",
        "expense",
        "increase",
        "year",
        "year",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "sage",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "sale",
        "enable",
        "co",
        "fund",
        "operating",
        "expense",
        "capex",
        "requirement",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}